Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
E-MYCIN E vs ERYTHROMYCIN AND BENZOYL PEROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
Topical: Apply a thin layer to affected areas once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic